A record of what JPMorgan Analysis said publicly, with the source. Not advice.
Pending — not yet graded
“JPMorgan has upgraded Torrent Pharma to 'overweight', anticipating an 18% upside in the stock. This upgrade led to a 4% surge in Torrent Pharma shares, indicating a bullish outlook for the company.”
JPMorgan Analysis’s track record (trackable calls only): 30 graded calls · 95% CI 30–64%
Torrent Pharmaceuticals LtdBullishCalled 27 Jun 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee JPMorgan Analysis’s full track record